Riskified Ltd. RSKD 深 滬
等待開盤 08-08 09:30:00 美东时间
5.09
-0.110
-2.12%
華盛通- 最 高5.2463
- 今 開5.24
- 成交量 29.80万股
- 最 低 5.045
- 昨 收 5.20
- 總市值 8.09亿
- 52周最高 5.995
- 市盈率 靜 --
- 換手率 0.19%
- 52周最低 3.94
- 委 比 42.86%
- 總股本 1.59亿
- 歷史最高 40.48
- 量 比 0.68
- 振 幅 3.87%
- 歷史最低 3.43
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
UBS Maintains Neutral on Riskified, Raises Price Target to $5.75
UBS analyst Timothy Chiodo maintains Riskified (NYSE:RSKD) with a Neutral and raises the price target from $5.5 to $5.75.
05-15 21:41
Riskified Affirms FY2025 Sales Guidance of $333.00M-$346.00M vs $339.97M Est
Riskified (NYSE:RSKD) affirms FY2025 sales outlook from $333.00 million-$346.00 million to $333.00 million-$346.00 million vs $339.97 million estimate.
05-14 18:52
Riskified Q1 Adj. EPS $0.03 Beats $0.01 Estimate, Sales $82.39M Beat $79.23M Estimate
Riskified (NYSE:RSKD) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.01 by 200 percent. This is a 25 percent decrease over earnings of $0.04 per share from the same period
05-14 18:51
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
美股大行评级 | 花旗：维持爱科集团"中性"评级，目标价从95美元升至98美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1108674722736648193.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从18美元升至19美元</p> <p>• Ascendiant Capital：维持Daxor Corp.(DXR)"买入"评级，目标
03-18 10:15
美股大行评级 | 杰富瑞：上调爱彼迎评级至"买入"，目标价从165美元升至185美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106138546093002753.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 瑞杰金融：上调Trevi Therapeutics(TRVI)评级至"强烈买入"，目标价从9美元升至29美元</p> <p>• Needham：维持Trevi Therapeutics(TRVI)"买入"评级，目标价从8美
03-11 10:13
JP Morgan Maintains Neutral on Riskified, Lowers Price Target to $6
JP Morgan analyst Reginald Smith maintains Riskified (NYSE:RSKD) with a Neutral and lowers the price target from $7 to $6.
03-10 23:22
Barclays Remains a Hold on Riskified (RSKD)
In a report released today, Ramsey El Assal from Barclays maintained a Hold rat...
03-10 15:28
